Drug Development and Regulation

Drug Discovery & Preclinical - Molecule Mission

• Discovery:
  • Target identification (key receptor/enzyme in disease).
  • Screening (HTS, virtual) for initial 'hits'.
  • Lead optimization (↑potency, ↑selectivity, favorable ADMET).
• Preclinical (Animal models; ≥2 species; Good Laboratory Practice - GLP):
  • Pharmacokinetics (ADME profile).
  • Pharmacodynamics (efficacy, mechanism of action - MOA).
  • Toxicology:
    • Acute toxicity (single dose, LD50).
    • Subacute/Chronic (repeated dose effects).
    • Reproductive tox. (teratogenicity, Segment II).
    • Genotoxicity (mutagenic potential, Ames test).
    • Carcinogenicity (long-term, 2-year rodent bioassay).

⭐ NOAEL (No Observed Adverse Effect Level) from preclinical studies is critical for determining the safe starting dose in Phase 1 human trials.

• 📌 An IND (Investigational New Drug) application to regulatory authorities (CDSCO-India, FDA-USA) is mandatory before human trials.

Clinical Trials - Human Test Voyage

• Investigational New Drug (IND) Application: Submitted to regulatory authority (e.g., CDSCO in India) before human trials.
• Phase 0 (Exploratory/Microdosing):
  • Participants: ~10-15 healthy volunteers.
  • Purpose: Preliminary Pharmacokinetics (PK)/Pharmacodynamics (PD) data, not therapeutic.
• Phase I (Human Pharmacology & Safety):
  • Participants: 20-80 healthy volunteers (or patients for specific conditions like cancer).
  • Purpose: Assess safety, tolerability, Maximum Tolerated Dose (MTD), PK/PD.
  • 📌 Mnemonic: "S" for Safety, Smallest group.
• Phase II (Therapeutic Exploratory):
  • Participants: 100-300 patients with the target disease.
  • Purpose: Evaluate efficacy, determine optimal dose range, identify common short-term side effects.
• Phase III (Therapeutic Confirmatory):
  • Participants: 1000-3000+ diverse patients.
  • Purpose: Confirm efficacy in a larger population, monitor adverse reactions, compare with standard treatment (Randomized Controlled Trials - RCTs). Forms basis for New Drug Application (NDA).
• New Drug Application (NDA): Submitted to regulatory authority for marketing approval.
• Phase IV (Post-Marketing Surveillance):
  • Participants: Large patient population using the approved drug.
  • Purpose: Monitor long-term safety, detect rare side effects, explore new indications, assess drug interactions. Pharmacoepidemiology.

⭐ Declaration of Helsinki: A set of ethical principles regarding human experimentation developed for the medical community. Essential for guiding clinical trial conduct globally and in India.

Indian Drug Regulation - Desi Rule Roadmap

• Primary Legislation: Drugs & Cosmetics Act, 1940 & Rules, 1945.
• Apex Body: Central Drugs Standard Control Organization (CDSCO).
  • Headed by: Drug Controller General of India (DCGI).
  • Functions: New drug approval, clinical trial oversight, import/export control, drug quality assurance.
• Key Supporting Bodies:
  • Indian Pharmacopoeia Commission (IPC): Publishes Indian Pharmacopoeia (IP), setting drug standards.
  • National Pharmaceutical Pricing Authority (NPPA): Fixes/revises drug prices via Drug Price Control Orders (DPCO).
• Crucial Schedules:
  • Schedule Y: Detailed guidelines for clinical trials.
  • Schedule M: Good Manufacturing Practices (GMP) requirements.
  • Schedule H & H1: Prescription-only drugs; H1 requires separate register.

⭐ The Drugs and Cosmetics Act, 1940, and its subsequent Rules, 1945, form the bedrock of drug regulation in India, governing import, manufacture, distribution, and sale of drugs and cosmetics.

📌 Mnemonic: "Central Drugs Standard Control Organization Controls Drugs Safely Country Over" (CDSCO functions).

Ethical & GCP Standards - Fair Play Pharma

• Declaration of Helsinki: Guiding ethical principles for medical research involving human subjects.

  • ⭐ Key ethical pillars (Belmont Report): Respect for Persons, Beneficence, Justice.

• Informed Consent (IC): Voluntary, informed, documented participant agreement. Essential before trial procedures.
• Institutional Review Board (IRB)/Independent Ethics Committee (IEC): Reviews & approves trial protocols; ensures subject safety & rights.
• Good Clinical Practice (GCP): ICH-GCP international standard for trial conduct, data quality, ethical compliance.
• Clinical Trial Registry - India (CTRI): Mandatory public recording of all clinical trials conducted in India.

High‑Yield Points - ⚡ Biggest Takeaways

• Clinical trial phases: Phase I (safety), Phase II (efficacy), Phase III (confirmatory), Phase IV (post-marketing).
• CDSCO, led by DCGI, is India's primary drug regulatory authority.
• Schedule Y dictates clinical trial guidelines in India.
• Orphan drugs are for rare diseases, often fast-tracked.
• IND (Investigational New Drug) application precedes human trials.
• PvPI (Pharmacovigilance Programme of India) monitors ADRs.
• NDA (New Drug Application) is for marketing approval after successful trials.